Biotechnology

ABBISKO-B

Affiliate of Huayu-B Obtains FDA Approval for New Drug Clinical Trial Application

HUT-B's Self-Developed Drug ABSK061 Receives FDA Orphan Drug Designation

Hengyu Biopharma's Irpagratinib Combination Therapy Completes First Patient Dosing in Phase II Clinical Trial for First-Line Treatment of Advanced Hepatocellular Carcinoma

Shanghai andy Biopharmaceutical ABSK061 Receives Rare Pediatric Disease Designation from FDA

Honor-B Publishes Phase III Clinical Trial Results for Novel Drug ABSK021

Horus-B's CSF-1R Inhibitor Phase III Study Results Published in The Lancet

Honor-B reports 95% YoY net profit growth in 2025, achieving annual profitability for the second consecutive year

ABBISKO-B released FY2025 9 Months Earnings on March 2, 2026 (BJT), with actual revenue of HKD 662.77 M and EPS of HKD 0.3131

ABBISKO-B released FY2025 Q3 earnings on March 2, 2026 (BJT) with actual revenue of HKD 0 and EPS of HKD -0.239

ABBISKO-B released FY2025 Q4 earnings on March 2 After-Market (BJT), actual revenue HKD 0, actual EPS HKD -0.2431

ABBISKO-B released FY2025 Annual Earnings on March 2 After-Market (BJT): Actual Revenue HKD 669.02 M (Forecast HKD 710.36 M), Actual EPS HKD 0.0966 (Forecast HKD 0.2726)

ABBISKO-B to Release FY2025 Earnings on March 2 After-Market (BJT), Forecast Revenue HKD 716.4 M, EPS HKD 0.1091

HUTL-B's Irpagratinib Receives FDA Fast Track Designation, Global Phase 1 Clinical Trial Successfully Dosed First Patient

Hua Medicine's ABSK021 Approved by NMPA

And 佑 Pharmaceuticals' new drug ABSK021 NDA accepted by FDA

CICC Maintains 2025/2026 Earnings Forecast and Target Price for AcuBIOTECH

Affiliate of Honor Biopharma Secures Approval for New Drug ABSK141 Clinical Trials

NMPA Approves Equillium's Beijiemai® for Specific Patient Treatment

Hengyue Biopharma's ABSK061 Completes First Patient Dosing in Phase II Clinical Trial for Achondroplasia Children

Hualyx Pharmaceutical Announces Positive Phase II Clinical Study Results of ABSK043 Combined with Furmonetinib for NSCLC and Regulatory Approval for Further Studies

I.CENTURY HLDG

RIVERINE CHINA

KOS TALENT GP

CHINA CBS INTL

NATURE ENERGY T

DIGIT HOLLYWOOD

REDCO HEALTHY

ZXZN QI-HOUSE

ASIA PIONEER

HUISHENG INTL

HeYu Pharmaceutical 2024 Annual Performance Conference

02256

Abbisko Cayman Limited plans to modernize its governance by updating its Memorandum and Articles of Association to comply with Hong Kong's new listing requirements. The amendments will allow for hybrid or fully virtual general meetings and electronic voting, pending shareholder approval at the May 20, 2026 annual general meeting. This initiative aims to enhance shareholder engagement and operational efficiency while adhering to regulatory standards. The current analyst rating for Abbisko's stock (HK:2256) is a Buy, with a price target of HK$27.10.

Tip Ranks

Abbisko Moves to Modernise Governance With Digital-Ready Articles Update

562050

512290

159837

513120

516500

The results of the Phase III MANEUVER study of the anti-tumor targeted drug Abemaciclib (ABSK021) by ABBISKO-B were published in The Lancet on March 5th. The study included 94 subjects across more than 30 clinical centers worldwide, demonstrating significant efficacy of Abemaciclib in treating patients with tenosynovial giant cell tumors (TGCT) and showing good safety characteristics, indicating its potential in the treatment of related indications

AASTOCKS

Hwabao WP CSI Pharmaceuticals ETF

Guotai CSI Bio-medicine ETF

E Fund CSI Biotechnology Theme ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

Yinhua CSI Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

China Merchants CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC SSE STAR Biology and Medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund CSI 300 Health Care ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Abbisko's anti-tumor targeted drug Bejimai Phase III study results published in The Lancet

Abbisko Cayman Limited's subsidiary, Abbisko Therapeutics, announced the publication of its Phase 3 MANEUVER trial results for pimicotinib in The Lancet. The study demonstrated significant efficacy and a favorable safety profile in treating tenosynovial giant cell tumor, supporting regulatory reviews in China and the U.S. The publication enhances Abbisko's standing in oncology, with potential commercial prospects, although global commercialization remains uncertain. The latest analyst rating for Abbisko Cayman Limited (HK:2256) is a Hold with a price target of HK$13.00.

Abbisko’s TGCT Drug Pimicotinib Clears Key Global Milestone With Lancet Phase 3 Publication

Abbisko Cayman (SEHK:2256) reported full year 2025 results with sales of CNY612.12 million and net income of CNY55.25 million, leading to a basic EPS of CNY0.09. The stock saw a 4.76% increase to HK$11.88 post-release, but has a 90-day return of 16.63% and a year-to-date decline of 8.76%. The current P/E ratio of 127.6x is significantly higher than industry averages, raising concerns about its valuation amidst forecasts of declining earnings. However, a DCF analysis suggests a potential fair value of HK$36.25, indicating possible market caution on long-term cash generation.

Simplywall

Assessing Abbisko Cayman (SEHK:2256) Valuation After Full Year 2025 Earnings Release

Abbisko Cayman Limited has announced the first patient dosing in a Phase I/II trial of ABSK141, a small-molecule inhibitor targeting KRAS G12D mutations in advanced solid tumors. This milestone, cleared by the U.S. FDA and China’s NMPA, positions Abbisko to compete in KRAS-targeted therapy, an area of significant industry focus. Preclinical data suggest ABSK141 may provide best-in-class oral bioavailability and anti-tumor activity. The current analyst rating for Abbisko Cayman Limited (HK:2256) is a Hold with a price target of HK$13.00.

Abbisko Advances KRAS G12D Cancer Program With First Patient Dosed in ABSK141 Trial

ABBISKO-B announced that on March 3rd, the company's founder, CEO, and chairman Dr. Xu Yaochang purchased a total of 45,000 shares in the open market at an average price of HKD 11.26 per share. After the purchase, Dr. Xu holds a total of 81,769,900 shares, accounting for 12.02% of the company's total share capital

The founder and chairman of ABBISKO increased their holdings by 45,000 shares at an average price of 11.26 yuan

Abbisko Cayman Limited has dosed the first U.S. patient in a global Phase I trial of irpagratinib, an FGFR4 inhibitor for advanced hepatocellular carcinoma. The drug has received Fast Track designation from the U.S. FDA and Breakthrough Therapy designation in China. Early data show durable antitumor activity and a favorable safety profile. Abbisko aims to accelerate global development and commercialization of irpagratinib, which shows promise in first-line HCC treatment. The current analyst rating for Abbisko stock (HK:2256) is a Hold with a price target of HK$13.00.

Abbisko Advances FGFR4 Inhibitor Irpagratinib With First U.S. Patient Dosed in Global HCC Trial

ABBISKO-B announced that its self-developed FGFR4 inhibitor Irpagratinib (ABSK-011) has received Fast Track designation from the U.S. FDA for patients with hepatocellular carcinoma who have previously received immune checkpoint inhibitors and multi-target kinase inhibitors and have FGF19 overexpression. This will accelerate its global clinical development and regulatory review process. ABBISKO will continue to advance the international clinical layout of this project, committed to providing precise and effective innovative treatment solutions for global HCC patients

HeYu's independently developed new drug has received FDA Fast Track designation

ABBISKO-B(02256.HK)